1. Market Research
  2. > Pathology
About 200 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Breast Implants Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product ; Application, Surface Type, and Geography

  • $ 4550
  • April 2020
  • 155 pages

The cancer is linked to breast implants; the FDA calls the cancer breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL).

  • Breast Cancer
  • Lymphoma
  • Medical Device
  • Prosthesis
  • Forecast

Potential Pipeline Disruptors

  • $ 4200
  • May 2017
  • 120 pages

FOLLICULAR LYMPHOMA TENDS TO BE INDOLENT AND DIFFUSE LYMPHOMA TENDS TO BE AGGRESSIVE.

  • Breast Cancer
  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy

Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison, Competitive Landscape - Global Forecasts to 2022

  • $ 4950
  • August 2018
  • 83 pages

lymphoma, thyroid cancer, breast cancer, melanoma, GIST, colon, and lung cancer monitoring for common mutations. ctDNA has found significant use as it provides faster detection than conventional techniques, such as CT scans and other imaging technologies.

  • Breast Cancer
  • Genetic Testing
  • Lymphoma
  • United States
  • Market Size

Potential "Pipeline Disruptors" - New Products That Will Drive The Future Pharmaceutical Market

  • $ 4200
  • May 2017
  • 120 pages

(% market share) CHAPTER ##: PIPELINE DISRUPTORS: LYMPHOMA MARKET OPPORTUNITY Non-Hodgkin' s Lymphoma Table ##-##: Classification of Non-Hodgkin' s Lymphomas Hodgkin' s Lymphoma Figure ##-##: Global Incidence and Mortality of Lymphoma by Country, 2012* THE HEAVY HITT

  • Breast Cancer
  • Lymphoma
  • Monoclonal Antibody
  • Pathology
  • Targeted Therapy

Global Biopsy Device Market, Biopsy Procedure Volume, Company Product Analysis and Forecast To 2022

  • $ 1600
  • January 2018
  • 240 pages

This may be particularly true with trying to make a diagnosis of lymphoma.

  • Biopsy
  • Breast Cancer
  • Diagnostics
  • Injectable Delivery
  • Lymphoma

PARP Inhibitors in Oncology

  • $ 7995
  • September 2018
  • 116 pages

lymphoma) Orphan Drug Designation (ovarian) Fast Track Designation (ovarian) NCT## NCT## NCT## NCT## NCT## NCT## NCT## NCT## NCT## NCT## NCT## NCT## Phase III Phase II Designations SmallMoleculePARPInhibitors End date:

  • Breast Cancer
  • Clinical Trial
  • Targeted Therapy
  • Therapy
  • United States

Global Breast Biopsy Market 2017-2021

  • $ 2500
  • March 2017
  • 70 pages

There are various types of cancer such as skin, breast, colorectal, lung, lymphoma, and prostate cancers.

  • Biopsy
  • Breast Cancer
  • Lymphoma
  • C.R. Bard, Inc.
  • Hologic, Inc.

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • June 2017
  • 416 pages

lymphoma kinase ALT AML AMNOG alanine transaminase acute myeloid leukemia Arzneimittelmarkt-Neuordnungsgesetz Arimidex, Tamoxifen Alone or in Combination trial blood brain barrier breast conserving surgery Boehringer Ingelheim bis in die (twice a day) Bristol-Myers Squibb Bundled Payments f

  • Breast Cancer
  • Cancer
  • Lymphoma
  • Pathology
  • Therapy

Institute of Cancer Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • September 2018
  • 81 pages

The other types of blood cancer are leukaemias and lymphomas.

  • Breast Cancer
  • Cancer
  • Lymphoma
  • Specialty Hospital
  • United Kingdom

Global Solid Tumors Drugs Market 2016-2020

  • $ 2500
  • June 2016
  • 156 pages

Organizations such as the Lymphoma Club and the Lymphoma Research Foundation (LRF) are creating awareness of NHL.

  • Breast Cancer
  • Cancer
  • Lymphoma
  • Therapy
  • F. Hoffmann-La Roche Ltd.

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • December 2016
  • 510 pages

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the ...

  • Breast Cancer
  • Epidemiology
  • Lymphoma
  • Targeted Therapy
  • Therapy

Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 78 pages

As of September 2017, the drug candidate was in Phase I stage for T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

  • Breast Cancer
  • Hospital
  • Lymphoma
  • Pharmaceutical
  • Therapy

Poly [ADP Ribose] Polymerase 2 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 181 pages

IT WAS UNDER DEVELOPMENT FOR THE TREATMENT OF MANTLE CELL LYMPHOMA.

  • Breast Cancer
  • Hospital
  • Lymphoma
  • Targeted Therapy
  • Therapy

Biopsy Device Market (By Country Wise and Product Segment) and Biopsy Procedure Volume Forecast To 2020 - Global Analysis

  • $ 1400
  • January 2017
  • 233 pages

This may be particularly true with trying to make a diagnosis of lymphoma.

  • Biopsy
  • Breast Cancer
  • Diagnostics
  • Injectable Delivery
  • Lymphoma

Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market

  • $ 4995
  • April 2017
  • 1 pages

Lymphoma Caspase Like Apoptosis Regulatory Protein Berg Oncternal Therapeutics University of Michigan Centre National de la Small molecule mAb Small molecule Small molecule Undisclosed TPK receptor Kinase DNA (Cytosine ## ) ubidecarenone UC-## UM-## UVI-## v-DOS Vaccine ## to Target MUC-##

  • Breast Cancer
  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy

Cyclin Dependent Kinase 4 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 173 pages

As a third line therapy for follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia(CLL), diffuse large B-cell lymphoma (DLBCL) and relapsed/ refractory acute m

  • Breast Cancer
  • Lymphoma
  • Pharmaceutical
  • Targeted Therapy
  • Therapy

Cyclin Dependent Kinase 6 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 168 pages

As a third line therapy for follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia(CLL), diffuse large B-cell lymphoma (DLBCL) and relapsed/ refractory acute m

  • Breast Cancer
  • Lymphoma
  • Pharmaceutical
  • Targeted Therapy
  • Therapy

Histone Deacetylase 8 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020
  • 46 pages

It is in Phase I stage of development for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma including diffuse large B-Cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, transformed indolent lymphoma and mul

  • Breast Cancer
  • Lymphoma
  • Therapy
  • Product Initiative
  • Chipscreen Biosciences Ltd

Anaplastic Oligoastrocytoma - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 83 pages

The drug candidate is in Phase I/ II stage of development for the treatment of small lymphocytic lymphoma, lymphoblastic lymphoma, splenic, nodal and extra nodal marginal zone lymphoma, mantle cell lymphoma and follicular lymphoma as first line therap

  • Breast Cancer
  • Lymphoma
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.

Aurora Kinase A - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 85 pages

As of May 2018, the drug candidate was in Phase II stage of development for Waldenstrome macroglobulinemia, B-cell non-hodgkin lymphoma including diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone B-cell lymphoma, follicular lymphoma, and Burkitt

  • Breast Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Millennium

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on